Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive Multiple Sclerosis with a Sustained Release Glatiramer Acetate Depot

NESS ZIONA, Israel, March 30, 2022 (GLOBE NEWSWIRE) — Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable solutions mainly for neurological indications, announced today that the company has been granted U.S. Patent No. 11,167,003 entitled: “Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems.”

GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone^®/Glatopa^®), designed to be administered as an intramuscular injection once every four weeks. GA Depot is currently in the final stages of a multinational Phase III clinical study where it is being evaluated for treatment of relapsing forms of multiple sclerosis (RMS). GA Depot is also currently being evaluated in a multinational Phase II for primary progressive multiple sclerosis (PPMS).

Ehud Marom, Chairman and Chief Executive Officer of Mapi, said, “Developing and extending our IP portfolio is an important part of Mapi’s strategy and we are pleased to have been granted this U.S. patent which covers our long-acting GA for both PPMS and secondary progression multiple sclerosis.”

Based on the initial efficacy and safety results in the ongoing Phase II study in PPMS and the patent protection, the company is seeking a partner to support the Phase III development and co-marketing of GA Depot for PPMS.

Mapi will present two posters featuring clinical data on GA Depot in RRMS and PPMS at the forthcoming American Academy of Neurology annual meeting, to take place April 2 – 7, 2022.